Inverna Therapeutics Forms Scientific Advisory Board of RNA & Neurodegenerative Experts

Press release

Odense, Denmark – October 29, 2025 – Inverna Therapeutics (Inverna), a Danish biotech company advancing RNA oligonucleotide-based therapeutics, today announced the establishment of its Scientific Advisory Board (SAB). The SAB is comprised of internationally recognized leaders whose expertise spans RNA biology, neurodegenerative disease, proteomics, and translational medicine.
“We are privileged to welcome this remarkable group of scientific leaders to our SAB” said Poul Sørensen, CEO. “Their collective expertise will play a pivotal role in shaping our research strategy and ensuring our therapies are positioned to meet the needs of patients effectively and efficiently”.

Inverna’s Scientific Advisory Board Members:

Prof. Adrian R. Krainer, PhD is the St. Giles Foundation Professor at Cold Spring Harbor Laboratory, NY and has spent four decades of expertise in advancing RNA splicing research and ASO-based therapies correcting splicing defects in neurological and genetic diseases and for cancer therapy. He is the co-developer of Spinraza® (nusinersen), the first FDA-approved antisense therapy for spinal muscular atrophy, co-founder and director of Stoke Therapeutics, and serving on multiple scientific advisory boards. Dr. Krainer is a globally recognized researcher, offering unparalleled expertise in RNA biology, antisense drug development, and translational innovation to the advancement of splice-modulating therapies.

Dr. Laura Sepp-Lorenzino is the Senior Scientific Advisor at Intellia Therapeutics where she previously served as Chief Scientific Officer overseeing research and early development. In addition, she held previous leadership roles at Alnylam, Merck, and Vertex. Dr. Sepp-Lorenzino is a recognized authority in RNA therapeutics, oligonucleotide drug development, and translational R&D strategy, and serves on multiple boards and advisory panels that guide advancements in gene and RNA medicines.

Prof. Michelle L. Hastings is Pfizer Upjohn Research Professor of Pharmacology at the University of Michigan Medical School and Director of the RNA Therapeutics Program at the Center for RNA Biomedicine. Dr. Hastings is a pioneering figure in RNA-based therapeutics, with landmark contributions to antisense oligonucleotide development for splicing modulation in genetic and neurodegenerative diseases

Dr. Niels Skotte is Assistant Professor and Principal Investigator at the University of Copenhagen, Department of Drug Design and Pharmacology. His group focuses on clinical proteomics and molecular neuropathology in neurodegenerative diseases. Dr. Skotte has pioneered allele-selective antisense oligonucleotide therapeutics and novel intervention strategies targeting mutant huntingtin gene expression, supporting translational and therapeutic innovation in CNS disorders.

“The formation of our Scientific Advisory Board marks a significant milestone for Inverna,” said Brage S. Andresen, PI and Chief Scientific Officer of Inverna Therapeutics. “Our SAB brings together exceptional scientific minds who share our vision for RNA-based innovation and help us accelerate the development of critical therapies.” The newly formed SAB will provide guidance on the company’s scientific direction, facilitate translational strategies from discovery to clinical development, and support innovative approaches to address complex genetic and neurodegenerative diseases. This collaboration underscores Invernas’s commitment to leveraging world-class expertise to accelerate therapeutic innovation and patient impact.

About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from the University of Southern Denmark in Odense and nurtured by Argobio Studio (www.argobiostudio.com), a launch platform for Europe’s best medicinal science. With its proprietary drug discovery platform, Inverna is dedicated to developing transformative RNA therapeutics based on RNA splicing modulation. The company aims to rapidly design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. With a strong scientific foundation and an experienced, talented team, Inverna is committed to advancing novel RNA therapeutics and bringing hope to patients.

Contact :